Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

HRTX

Heron Therapeutics Inc

May 08 • 04:00PM ET

3.01

Dollar change +0.14
Percentage change 4.88	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO SCHA VTWO VHT ITOT IWC FESM

Index	RUT	P/E	-	EPS (ttm)	-0.62	Insider Own	5.10%	Shs Outstand	150.29M	Perf Week	28.63%
Market Cap	453.43M	Forward P/E	301.00	EPS next Y	0.01	Insider Trans	4.20%	Shs Float	142.96M	Perf Month	7.50%
Income	-80.95M	PEG	-	EPS next Q	-0.04	Inst Own	70.90%	Short Float	17.79%	Perf Quarter	33.19%
Sales	132.10M	P/S	3.43	EPS this Y	86.25%	Inst Trans	7.17%	Short Ratio	10.82	Perf Half Y	306.76%
Book/sh	-0.22	P/B	-	EPS next Y	109.09%	ROA	-36.90%	Short Interest	25.43M	Perf Year	23.36%
Cash/sh	0.47	P/C	6.34	EPS next 5Y	47.50%	ROE	-2408.88%	52W Range	0.50 - 3.22	Perf YTD	77.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.01%	ROI	-56.90%	52W High	-6.52%	Beta	1.72
Dividend TTM	-	Quick Ratio	1.90	Sales past 5Y	17.85%	Gross Margin	57.08%	52W Low	502.00%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	2.47	EPS Y/Y TTM	49.36%	Oper. Margin	-87.07%	RSI (14)	61.89	Volatility	10.22% 8.41%
Employees	126	Debt/Eq	-	Sales Y/Y TTM	16.05%	Profit Margin	-61.28%	Recom	1.25	Target Price	6.75
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	92.39%	Payout	-	Rel Volume	1.65	Prev Close	2.87
Sales Surprise	5.13%	EPS Surprise	73.15%	Sales Q/Q	17.07%	Earnings	May 07 BMO	Avg Volume	2.35M	Price	3.01
SMA20	12.21%	SMA50	10.73%	SMA200	64.30%	Trades		Volume	3,886,923	Change	4.88%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-23-24	Initiated	CapitalOne	Overweight	$6
Mar-13-24	Reiterated	Needham	Buy	$4 → $5
May-27-20	Initiated	Guggenheim	Buy	$24
Feb-20-20	Reiterated	Needham	Buy	$50 → $48
Jan-16-19	Reiterated	Needham	Buy	$66 → $64
Apr-05-18	Initiated	Evercore ISI	Outperform	$56
Mar-19-18	Reiterated	Mizuho	Buy	$28 → $35
Mar-01-18	Reiterated	Needham	Buy	$28 → $30
Jan-03-18	Initiated	Leerink Partners	Outperform	$22
Sep-27-17	Initiated	Northland Capital	Outperform	$40
Feb-27-17	Initiated	Needham	Buy	$28
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy	$45
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy	$45
Sep-23-15	Reiterated	Leerink Partners	Outperform	$38 → $57
Sep-02-15	Initiated	BofA/Merrill	Buy	$46
Aug-03-15	Reiterated	Brean Capital	Buy	$40 → $45
Jun-30-15	Reiterated	JMP Securities	Mkt Outperform	$25 → $33
Jun-19-15	Reiterated	Leerink Partners	Outperform	$26 → $38

Show Previous Ratings

Today 12:30PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:10AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ... (GuruFocus.com)
May-07-24 12:54PM	HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:34AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:05AM	Loading…
09:05AM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Apr-30-24 10:01AM	Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know (Zacks) -7.20%
Apr-24-24 08:00AM	Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (PR Newswire) -5.36%
Apr-11-24 04:05PM	Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City (PR Newswire) +7.69%
Mar-28-24 04:05PM	Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-13-24 09:19AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +27.54%
07:04AM	Q4 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 06:00PM	Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics (Zacks)
05:33PM	Loading…
05:33PM	Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023 (GuruFocus.com)
04:34PM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Mar-07-24 09:15AM	Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Feb-28-24 08:00AM	Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 (PR Newswire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-06-24 12:00PM	All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy (Zacks)
Jan-25-24 06:44AM	Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion (Zacks)
Jan-24-24 01:47PM	Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod (Benzinga) +18.86%
Jan-23-24 08:00PM	Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures (PR Newswire) -5.98%
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)
09:55AM	Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-07-24 05:00PM	Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain (PR Newswire)
Dec-10-23 12:23PM	Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master (Associated Press Finance)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
07:33PM	Loading…
Nov-28-23 07:33PM	Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth (InvestorPlace) -7.95%
Nov-15-23 10:17AM	Heron Therapeutics Inc (HRTX) Raises 2023 Sales Guidance and Projects Positive EBITDA in 2024 (GuruFocus.com) +59.26%
08:51AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:46AM	Q3 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 06:00PM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:17PM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance (PR Newswire)
Nov-07-23 04:05PM	Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 (PR Newswire) +6.88%
Aug-24-23 09:29AM	11 Best Long-Term Penny Stocks to Buy Now (Insider Monkey)
Aug-15-23 01:30PM	Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +10.93%
12:48PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2023 Earnings Call Transcript (Insider Monkey)
09:47AM	Q2 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:29PM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -6.79%
04:05PM	Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates (PR Newswire)
Aug-07-23 04:05PM	Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 (PR Newswire)
10:50AM	Insiders Pour Millions Into These 2 Stocks Under $10 Heres Why Wall Street Thinks They Could Double (or More) (TipRanks)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE) +9.27%
Jul-24-23 09:02AM	Heron Therapeutics Announces Cost Reduction Plan and Restructuring (PR Newswire) +11.59%
09:00AM	Heron Therapeutics Announces $30 Million Private Placement Financing (PR Newswire)
Jun-23-23 04:05PM	Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer (PR Newswire)
Jun-12-23 09:00AM	Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer (PR Newswire)
May-11-23 05:15PM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.98%
04:12PM	Heron Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates (PR Newswire)
May-05-23 12:28PM	Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel (Simply Wall St.)
Apr-20-23 11:45AM	These 2 Growth Stocks Might Be Incredibly Undervalued Right Now (Motley Fool) -5.56%
09:00AM	Heron Therapeutics Announces Commercial Leadership Changes (PR Newswire)
Apr-17-23 04:05PM	Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference (PR Newswire) +5.13%
Apr-06-23 03:42PM	Why Heron Therapeutics Stock Has Been on Fire This Week (Motley Fool) +20.00%
02:01PM	Why Shares of Heron Therapeutics Jumped Thursday (Motley Fool)
Apr-03-23 09:00AM	Heron Therapeutics Announces New CEO and Board Chairman (PR Newswire) +17.88%
Mar-27-23 07:12AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2022 Earnings Call Transcript (Insider Monkey) -9.19%
Mar-24-23 06:43AM	Q4 2022 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -7.75%
Mar-23-23 09:28PM	Dow futures tick higher, banking crisis weighs (Investing.com)
05:35PM	Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates (PR Newswire)
Mar-13-23 09:00AM	Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE, Effective April 1, 2023 (PR Newswire) +11.11%
Mar-10-23 04:05PM	Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023 (PR Newswire) -5.68%
Mar-06-23 09:00AM	Heron Therapeutics Announces U.S. Commercial Launch of APONVIE for the Management of Postoperative Nausea and Vomiting in Adults (PR Newswire)
Feb-27-23 04:30PM	Heron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare Conference (PR Newswire)
Feb-22-23 09:00AM	Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital (PR Newswire) +10.88%
Jan-30-23 05:54AM	The past three years for Heron Therapeutics (NASDAQ:HRTX) investors has not been profitable (Simply Wall St.)
Jan-09-23 08:30AM	Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises (PR Newswire)
Dec-29-22 09:45AM	Heron Therapeutics Files For Expanded Use Of Zynrelef In Soft Tissue, Orthopedic Surgical Procedures (Benzinga) +9.78%
09:00AM	Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF (PR Newswire)
Dec-28-22 12:32PM	15 Most Shorted Stocks Hedge Funds Are Buying (Insider Monkey)
Dec-20-22 03:41PM	12 Best Affordable Stocks to Buy Under $5 (Insider Monkey)
Nov-21-22 04:05PM	Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference (PR Newswire)
Nov-15-22 10:14PM	7 Penny Stocks to Buy for 10-Bagger Returns (InvestorPlace)
Nov-10-22 05:44AM	Heron Therapeutics Third Quarter 2022 Earnings: In Line With Expectations (Simply Wall St.)
Nov-09-22 01:15PM	Analysts Cut Price Targets As Heron Therapeutics' Zynrelef Disappoints In Q3 (Benzinga) -12.75%
Nov-08-22 06:25PM	Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates (PR Newswire)
Nov-04-22 11:48AM	Hurry! 7 Pitiful Stocks to Sell Before 2022 Ends (InvestorPlace)
Nov-01-22 04:05PM	Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 (PR Newswire)
Sep-26-22 09:45AM	4 No-Brainer Penny Stocks to Buy if You Have Money to Invest (InvestorPlace)
Sep-23-22 09:19AM	10 Most Shorted Stocks in September (Insider Monkey) -7.66%
07:30AM	7 Unknown Biotech Stocks That Could Rocket in 2023 (InvestorPlace)
Sep-19-22 06:42AM	FDA Approves Heron Therapeutics' Post-Op Nausea Treatment (Benzinga)
Sep-16-22 02:49PM	Heron Therapeutics Announces U.S. FDA Approval of APONVIE (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) (PR Newswire)
Sep-12-22 07:37AM	3 Stocks Expecting Good News From the FDA (Motley Fool)
Aug-23-22 12:00PM	All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Buy (Zacks)
Aug-15-22 09:55AM	How Much Upside is Left in Heron Therapeutics (HRTX)? Wall Street Analysts Think 91% (Zacks)
Aug-09-22 02:10PM	Heron Shares Jump After Equity Financing, Q2 Earnings (Benzinga) +15.13%
09:15AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:01AM	Heron Therapeutics Announces $76.5 Million Private Placement Financing (PR Newswire)
08:00AM	Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates (PR Newswire)
Aug-02-22 04:05PM	Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 (PR Newswire)
Jul-21-22 06:32AM	Heron Therapeutics (NASDAQ:HRTX) shareholders have endured a 83% loss from investing in the stock three years ago (Simply Wall St.)
Jul-18-22 06:00PM	7 Biotech Stocks to Buy for Q3 (InvestorPlace)

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Forbes William P	EVP, Chief Development Officer	Nov 17 '23	Buy	1.09	25,000	27,250	79,000	Nov 21 12:19 PM
Collard Craig A	Chief Executive Officer	Nov 16 '23	Buy	0.92	150,000	137,970	186,496	Nov 17 12:37 PM
Duarte Ira	EVP, Chief Financial Officer	Nov 16 '23	Buy	0.89	85,000	75,599	85,000	Nov 17 12:36 PM
Forbes William P	EVP, Chief Development Officer	Nov 16 '23	Buy	0.94	50,000	46,995	54,000	Nov 20 10:07 AM
Morgan Adam	Director	Jul 21 '23	Buy	1.37	2,486,744	3,406,839	6,986,744	Jul 25 04:22 PM

Open in Screener

XAIR

Beyond Air Inc

May 08 • 04:00PM ET

1.29

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC VTWG VTWV URTY UWM

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	22.91%	Shs Outstand	45.90M	Perf Week	14.16%
Market Cap	59.21M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	13.61%	Shs Float	35.39M	Perf Month	-22.75%
Income	-66.70M	PEG	-	EPS next Q	-0.47	Inst Own	22.44%	Short Float	9.06%	Perf Quarter	-28.33%
Sales	0.69M	P/S	85.81	EPS this Y	-3.98%	Inst Trans	10.31%	Short Ratio	10.62	Perf Half Y	-38.13%
Book/sh	0.59	P/B	2.20	EPS next Y	9.62%	ROA	-105.99%	Short Interest	3.21M	Perf Year	-76.76%
Cash/sh	0.69	P/C	1.88	EPS next 5Y	-	ROE	-185.90%	52W Range	1.06 - 6.36	Perf YTD	-34.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	9.16%	ROI	-179.27%	52W High	-79.72%	Beta	-0.01
Dividend TTM	-	Quick Ratio	3.26	Sales past 5Y	-54.80%	Gross Margin	-395.86%	52W Low	21.70%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	3.39	EPS Y/Y TTM	-25.60%	Oper. Margin	-9341.22%	RSI (14)	46.96	Volatility	10.60% 12.00%
Employees	98	Debt/Eq	0.81	Sales Y/Y TTM	-	Profit Margin	-9680.99%	Recom	1.00	Target Price	12.60
Option/Short	Yes / Yes	LT Debt/Eq	0.79	EPS Q/Q	-17.28%	Payout	-	Rel Volume	1.25	Prev Close	1.29
Sales Surprise	-12.96%	EPS Surprise	7.41%	Sales Q/Q	-	Earnings	Feb 12 AMC	Avg Volume	301.87K	Price	1.29
SMA20	2.16%	SMA50	-15.50%	SMA200	-37.75%	Trades		Volume	375,885	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-23	Initiated	Piper Sandler	Overweight	$10
Jun-15-23	Initiated	BTIG Research	Buy	$15
Apr-28-21	Initiated	Truist	Buy	$12
Oct-22-19	Initiated	Oppenheimer	Outperform	$9

May-01-24 07:00AM	Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
Mar-21-24 12:00PM	Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.84%
Mar-20-24 09:00AM	Beyond Air Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire)
Feb-13-24 08:51AM	Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcript (Insider Monkey) -17.67%
Feb-12-24 04:05PM	Beyond Air Reports Financial Results for Third Quarter of Fiscal Year 2024 (GlobeNewswire) +14.97%
08:00AM	Loading…
Jan-18-24 08:00AM	Beyond Air Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -5.02%
Dec-27-23 07:30AM	Beyond Cancer Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors (GlobeNewswire)
Dec-21-23 01:40AM	Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc (GuruFocus.com) +12.04%
Nov-15-23 04:05PM	Beyond Air To Participate in the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +23.57%
Nov-14-23 10:00AM	Beyond Air, Inc. (NASDAQ:XAIR) Q2 2024 Earnings Call Transcript (Insider Monkey) -31.03%
Nov-13-23 04:05PM	Beyond Air Reports Financial Results for Second Quarter of Fiscal Year 2024 (GlobeNewswire)
Nov-03-23 12:00PM	Beyond Cancer Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire) -6.91%
Oct-19-23 04:05PM	Beyond Air Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Oct-17-23 04:05PM	Beyond Air To Participate in the Truist Securities BioPharma Symposium (GlobeNewswire) +8.48%
07:30AM	Beyond Cancer Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice (GlobeNewswire)
07:30AM	Loading…
Oct-16-23 07:30AM	Beyond Cancer Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
07:00AM	Beyond Air Receives Innovative Technology Contract from Vizient for LungFit PH (GlobeNewswire)
Oct-04-23 07:30AM	Beyond Cancer Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-23 04:05PM	Beyond Air To Participate in the Roth MKM 2023 Healthcare Opportunities Conference (GlobeNewswire) -7.79%
Sep-27-23 09:00AM	Beyond Cancer to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting (GlobeNewswire)
Sep-18-23 04:05PM	Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder (GlobeNewswire) -7.95%
Sep-07-23 07:30AM	Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region (GlobeNewswire)
Sep-06-23 07:00AM	Beyond Air® To Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-10-23 04:05PM	Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024 (GlobeNewswire)
Aug-08-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +13.35%
Aug-07-23 04:05PM	Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD) (GlobeNewswire)
Aug-01-23 04:05PM	Beyond Air® To Participate in BTIGs 2023 Virtual Biotechnology Conference (GlobeNewswire)
Jul-28-23 10:13AM	Block upgraded, Southwest downgraded: Wall Street's top analyst calls (The Fly) +7.12%
Jul-24-23 04:05PM	Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -6.11%
Jun-22-23 04:05PM	Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023 (GlobeNewswire)
04:10PM	Loading…
Jun-15-23 04:10PM	Beyond Air® Secures up to $40 Million Debt Financing (GlobeNewswire)
04:05PM	Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem (GlobeNewswire)
Jun-09-23 06:34AM	Daily Vickers Top Insider Picks for 06/09/2023 (Argus Research)
Jun-08-23 06:43AM	Daily Vickers Top Insider Picks for 06/08/2023 (Argus Research)
Jun-07-23 08:25AM	Daily Vickers Top Insider Picks for 06/07/2023 (Argus Research)
Jun-06-23 06:34AM	Daily Vickers Top Insider Picks for 06/06/2023 (Argus Research)
Jun-05-23 06:44AM	Daily Vickers Top Insider Picks for 06/05/2023 (Argus Research)
Jun-02-23 06:56AM	Daily Vickers Top Insider Picks for 06/02/2023 (Argus Research)
Jun-01-23 06:29AM	Daily Vickers Top Insider Picks for 06/01/2023 (Argus Research)
May-31-23 06:40AM	Daily Vickers Top Insider Picks for 05/31/2023 (Argus Research)
May-30-23 06:50AM	Daily Vickers Top Insider Picks for 05/30/2023 (Argus Research)
May-26-23 06:59AM	Daily Vickers Top Insider Picks for 05/26/2023 (Argus Research)
May-25-23 06:38AM	Daily Vickers Top Insider Picks for 05/25/2023 (Argus Research)
May-24-23 06:43AM	Daily Vickers Top Insider Picks for 05/24/2023 (Argus Research)
May-23-23 06:33AM	Daily Vickers Top Insider Picks for 05/23/2023 (Argus Research)
May-22-23 07:49AM	Daily Vickers Top Insider Picks for 05/22/2023 (Argus Research)
May-19-23 07:03AM	Daily Vickers Top Insider Picks for 05/19/2023 (Argus Research)
May-18-23 06:39AM	Daily Vickers Top Insider Picks for 05/18/2023 (Argus Research)
May-17-23 06:35AM	Daily Vickers Top Insider Picks for 05/17/2023 (Argus Research)
May-16-23 04:05PM	Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast (GlobeNewswire)
Apr-19-23 09:00AM	Beyond Cancer Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting (GlobeNewswire)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research)
Mar-23-23 04:05PM	Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer (GlobeNewswire) -5.84%
Mar-14-23 04:35PM	Beyond Cancer to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting (GlobeNewswire) +6.59%
Mar-10-23 07:04AM	Daily Vickers Top Buyers & Sellers for 03/10/2023 (Argus Research)
Feb-22-23 07:00AM	Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023 (GlobeNewswire)
Feb-09-23 04:05PM	Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023 (GlobeNewswire) -6.21%
Jan-30-23 07:00AM	Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer (GlobeNewswire)
Jan-24-23 04:05PM	Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board (GlobeNewswire)
Jan-17-23 04:05PM	Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast (GlobeNewswire)
Dec-13-22 09:25AM	Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases (GlobeNewswire) +9.26%
Nov-17-22 04:05PM	Beyond Air® To Participate in Pipers 34th Annual Healthcare Conference (GlobeNewswire) -6.08%
Nov-10-22 09:00AM	Beyond Cancer Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (GlobeNewswire)
Nov-08-22 04:05PM	Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023 (GlobeNewswire)
Oct-24-22 07:30AM	Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022 (GlobeNewswire)
Oct-20-22 04:05PM	Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast (GlobeNewswire) +7.55%
Oct-17-22 04:05PM	Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022 (GlobeNewswire)
Oct-05-22 08:00AM	Beyond Cancer to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting (GlobeNewswire)
Oct-03-22 07:30AM	Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis (GlobeNewswire)
Sep-16-22 04:05PM	Beyond Air® To Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-23-22 08:00AM	Beyond Air® Affiliate Beyond Cancer Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov) (GlobeNewswire) +10.12%
Aug-11-22 04:05PM	Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2023 (GlobeNewswire)
Jul-27-22 04:05PM	Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast (GlobeNewswire)
Jun-28-22 04:10PM	Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022 (GlobeNewswire) -7.81%
04:05PM	Beyond Airs LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure (GlobeNewswire)
Jun-14-22 04:30PM	Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th (GlobeNewswire)
Jun-01-22 07:00AM	Beyond Cancer Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer (GlobeNewswire)
May-17-22 04:05PM	Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022 (GlobeNewswire) +7.84%
07:00AM	Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer (GlobeNewswire)
May-16-22 07:05AM	Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast (GlobeNewswire)
May-06-22 06:29AM	Loss-Making Beyond Air, Inc. (NASDAQ:XAIR) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Apr-25-22 04:05PM	Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022 (GlobeNewswire) +12.02%
07:00AM	Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022 (GlobeNewswire)
Apr-18-22 07:00AM	Beyond Air® to Participate in Three Upcoming Medical Conferences (GlobeNewswire)
Apr-11-22 07:00AM	Beyond Cancer Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect (GlobeNewswire) -7.95%
Mar-08-22 04:35PM	Beyond Cancer to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting (GlobeNewswire)
Feb-22-22 04:52AM	Beyond Air (NASDAQ:XAIR) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Feb-10-22 04:05PM	Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022 (GlobeNewswire)
Feb-08-22 08:00AM	Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022 (GlobeNewswire)
Feb-03-22 04:05PM	Beyond Air® Announces Two Appointments to Beyond Cancer Board of Directors (GlobeNewswire)
Jan-27-22 08:00AM	Beyond Air® Schedules Third Fiscal Quarter 2022 Financial Results Conference Call and Webcast (GlobeNewswire) -5.94%
Dec-14-21 09:15AM	Beyond Air Inc (XAIR) CEO and Chairman of the Board Steven A. Lisi Bought $341,200 of Shares (GuruFocus.com) +9.35%
Dec-10-21 09:14AM	Implied Volatility Surging for Beyond Air (XAIR) Stock Options (Zacks)
Dec-09-21 08:30AM	Beyond Air® Provides Regulatory Update for LungFit® PH (GlobeNewswire) -20.45%
05:56AM	Beyond Air Slides After LungFit Launch Delay (Investing.com)
Dec-01-21 08:00AM	Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer (GlobeNewswire)
Nov-18-21 04:05PM	Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer Private Placement (GlobeNewswire) -6.49%
Nov-11-21 04:05PM	Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022 (GlobeNewswire)
Nov-04-21 03:01PM	Beyond Air, Inc. (XAIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -9.44%
07:30AM	Beyond Air® Announces Formation of Beyond Cancer, a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors (GlobeNewswire)

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in developing a platform for nitric oxide generators and delivery systems. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Avniel Amir	Chief Business Officer	Dec 28 '23	Sale	2.05	13,733	28,217	0	Dec 29 04:23 PM
Avniel Amir	Chief Business Officer	Dec 28 '23	Sale	2.06	11,267	23,234	685,760	Dec 29 04:23 PM
Myers Jeff Lynn	Chief Medical Officer	Dec 27 '23	Sale	2.21	3,423	7,579	46,577	Dec 29 04:15 PM
Carey Robert	Director	Dec 18 '23	Buy	1.64	1,200,000	1,962,000	2,374,454	Dec 19 05:13 PM
Lisi Steven A.	CEO and Chairman of the Board	Dec 18 '23	Buy	1.63	77,775	126,797	1,536,471	Dec 19 05:15 PM
Gaul Michael A.	Chief Operating Officer	Nov 16 '23	Buy	1.77	10,000	17,700	88,150	Nov 17 04:15 PM
Carey Robert	Director	Aug 28 '23	Buy	2.69	250,000	673,750	1,225,160	Aug 29 04:10 PM
Carey Robert	Director	Aug 21 '23	Buy	2.76	75,050	207,453	975,160	Aug 22 04:10 PM
Carey Robert	Director	Aug 18 '23	Buy	2.64	13,614	35,940	900,110	Aug 22 04:10 PM
Gaul Michael A.	Chief Operating Officer	Jun 30 '23	Buy	4.51	5,000	22,550	78,150	Jul 05 04:05 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

HRTX

Heron Therapeutics Inc

XAIR

Beyond Air Inc

Upgrade your FINVIZ experience